PPAR-γ was shown to be involved in the activity of mesalazine, the standard first-line treatment for IBD patients with mild to moderately active ulcerative colitis [10], thus suggesting that colonic PPAR-γ could be a better therapeutic target in humans suffering from IBD [6,11,12,13]. This evidence concerns the gene PPARG and inflammatory bowel disease.